AVROBIO(AVRO) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights • Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1'2025 or early Q2'2025 • First subject dosed with TX000045 ("TX45") in APEX Phase 2 clinical trial in early October, with topline results expected in 2026 • Development Candidate TX002100 ("TX2100") selected for second program targeting patients with Hereditary Hemorrhag ...